Literature DB >> 11891147

Inhalation of aerosolized vitamin a: reversibility of metaplasia and dysplasia of human respiratory epithelia -- a prospective pilot study.

M Kohlhäufl1, K Häussinger, F Stanzel, A Markus, J Tritschler, A Mühlhöfer, A Morresi-Hauf, I Golly, G Scheuch, B H Jany, H K Biesalski.   

Abstract

The objective of this preliminary uncontrolled study was twofold: First, to assess the feasibility of retinyl palmitate inhalation and second, to analyze the changes of metaplastic lesions of the respiratory epithelium (metaplasia or dysplasia) following retinyl palmitate inhalation. The response to a daily dose of 18.000 I.U. retinyl palmitate by inhalation over a period of 3 month was assessed in 11 subjects (9 smokers, 2 ex-smokers). Using white-light bronchoscopy combined with autofluorescence bronchoscopy, bronchial biopsies were taken before and after a 3 month-period. The biopsy samples were evaluated blind by a referee lung pathologist. The overall response rate (remission or partial remission) was 56% (95% CI 0.30 0.79; p<0.05). These data suggest that inhalation of retinyl esters could be a promising therapeutical approach for chemoprevention of lung cancer. Vitamin A; chemoprevention; lung cancer; squamous metaplasia; dysplasia; retinoids

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11891147

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  8 in total

1.  Uptake of all-trans retinoic acid-containing aerosol by inhalation to lungs in a guinea pig model system--a pilot study.

Authors:  Michael W Schäffer; Somdutta Sinha Roy; Shyamali Mukherjee; David E Ong; Salil K Das
Journal:  Exp Lung Res       Date:  2010-12       Impact factor: 2.459

2.  Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer.

Authors:  Alfred Haynes; Madhu Sudhan Shaik; Abhijit Chatterjee; M Singh
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

3.  Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model.

Authors:  Suniket V Fulzele; Abhijit Chatterjee; Madhu Sudhan Shaik; Tanise Jackson; Mandip Singh
Journal:  Pharm Res       Date:  2006-08-11       Impact factor: 4.200

4.  Aerosol delivery of lentivirus-mediated O-glycosylation mutant osteopontin suppresses lung tumorigenesis in K-ras (LA1) mice.

Authors:  Arash Minai-Tehrani; Seung-Hee Chang; Jung-Taek Kwon; Soon-Kyung Hwang; Ji-Eun Kim; Ji-Young Shin; Kyeong-Nam Yu; Sung-Jin Park; Hu-Lin Jiang; Ji-Hye Kim; Seong-Ho Hong; Bitna Kang; Duyeoul Kim; Chan-Hee Chae; Kee-Ho Lee; George R Beck; Myung-Haing Cho
Journal:  Cell Oncol (Dordr)       Date:  2012-10-16       Impact factor: 6.730

5.  Combination Therapy of PPARgamma Ligands and Inhibitors of Arachidonic Acid in Lung Cancer.

Authors:  Jordi Tauler; James L Mulshine
Journal:  PPAR Res       Date:  2009-03-04       Impact factor: 4.964

6.  Transglutaminase 2 and nucleoside diphosphate kinase activity are correlated in epithelial membranes and are abnormal in cystic fibrosis.

Authors:  Kate J Treharne; O Giles Best; Anil Mehta
Journal:  FEBS Lett       Date:  2009-07-18       Impact factor: 4.124

7.  Surface activity of surfactant spiked with vitamin A.

Authors:  Vadim Bronshtein; Vugranam Venkatesh; Jas Aulakh; Philippe Chessex
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

8.  Vitamin A deficiency alters airway resistance in children with acute upper respiratory infection.

Authors:  Cleia T Amaral; Núbia N Pontes; Bruna L L Maciel; Hugo S M Bezerra; Ana Nataly A B Triesta; Selma M B Jeronimo; Stephen E McGowan; Vera M Dantas
Journal:  Pediatr Pulmonol       Date:  2012-07-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.